Ver registro no DEDALUS
Exportar registro bibliográfico

Metrics


Metrics:

No evidence for an association between the -36A>C phospholamban gene polymorphism and a worse prognosis in heart failure (2009)

  • Authors:
  • USP affiliated authors: BRUM, PATRICIA CHAKUR - EEFE
  • USP Schools: EEFE
  • DOI: 10.1186/1471-2261-9-33
  • Subjects: INSUFICIÊNCIA CARDÍACA; POLIMORFISMO
  • Language: Inglês
  • Imprenta:
  • Source:
  • Acesso online ao documento

    Online accessDOI or search this record in
    Informações sobre o DOI: 10.1186/1471-2261-9-33 (Fonte: oaDOI API)
    • Este periódico é de acesso aberto
    • Este artigo é de acesso aberto
    • URL de acesso aberto
    • Cor do Acesso Aberto: bronze
    • Licença: cc-by
    Informações sobre o Citescore
  • Título: BMC Cardiovascular Disorders

    ISSN: 1471-2261

    Citescore - 2017: 2.08

    SJR - 2017: 0.909

    SNIP - 2017: 0.816


  • Exemplares físicos disponíveis nas Bibliotecas da USP
    BibliotecaCód. de barrasNúm. de chamada
    EEFE1796541-10PRO 2009 049
    How to cite
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas

    • ABNT

      SANTOS, Diogo G. B.; MEDEIROS, Alessandra; BRUM, Patrícia Chakur; et al. No evidence for an association between the -36A>C phospholamban gene polymorphism and a worse prognosis in heart failure. BMC Cardiovascular Disorders, Londres, v. 9, 2009. Disponível em: < http://www.biomedcentral.com/1471-2261/9/33 > DOI: 10.1186/1471-2261-9-33.
    • APA

      Santos, D. G. B., Medeiros, A., Brum, P. C., Mill, J. G., Mansur, A. J., Krieger, J. E., & Pereira, A. C. (2009). No evidence for an association between the -36A>C phospholamban gene polymorphism and a worse prognosis in heart failure. BMC Cardiovascular Disorders, 9. doi:10.1186/1471-2261-9-33
    • NLM

      Santos DGB, Medeiros A, Brum PC, Mill JG, Mansur AJ, Krieger JE, Pereira AC. No evidence for an association between the -36A>C phospholamban gene polymorphism and a worse prognosis in heart failure [Internet]. BMC Cardiovascular Disorders. 2009 ; 9Available from: http://www.biomedcentral.com/1471-2261/9/33
    • Vancouver

      Santos DGB, Medeiros A, Brum PC, Mill JG, Mansur AJ, Krieger JE, Pereira AC. No evidence for an association between the -36A>C phospholamban gene polymorphism and a worse prognosis in heart failure [Internet]. BMC Cardiovascular Disorders. 2009 ; 9Available from: http://www.biomedcentral.com/1471-2261/9/33

    Referências citadas na obra
    O'Connell JB, Bristow MR: Economic impact of heart failure in the United States: time for a different approach. J Heart Lung Transplant. 1994, 13 (4): S107-112.
    Filho FMA: Epidemiologia da Insuficiência Cardíaca. Insuficiência Cardíaca. Edited by: Barretto ACP, Bocchi EA. 2003, São Paulo: Segmento, 13-22.
    Codd MB, Sugrue DD, Gersh BJ, Melton LJ: Epidemiology of idiopathic dilated and hypertrophic cardiomyopathy. A population-based study in Olmsted County, Minnesota, 1975–1984. Circulation. 1989, 80 (3): 564-572.
    Maron BJ, Towbin JA, Thiene G, Antzelevitch C, Corrado D, Arnett D, Moss AJ, Seidman CE, Young JB: Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation. 2006, 113 (14): 1807-1816. 10.1161/CIRCULATIONAHA.106.174287.
    Bowles KR, Bowles NE: Genetics of inherited cardiomyopathies. Expert Rev Cardiovasc Ther. 2004, 2 (5): 683-697. 10.1586/14779072.2.5.683.
    Haghighi K, Gregory KN, Kranias EG: Sarcoplasmic reticulum Ca-ATPase-phospholamban interactions and dilated cardiomyopathy. Biochem Biophys Res Commun. 2004, 322 (4): 1214-1222. 10.1016/j.bbrc.2004.07.164.
    Chiu C, Tebo M, Ingles J, Yeates L, Arthur JW, Lind JM, Semsarian C: Genetic screening of calcium regulation genes in familial hypertrophic cardiomyopathy. J Mol Cell Cardiol. 2007, 43 (3): 337-343. 10.1016/j.yjmcc.2007.06.009.
    Medin M, Hermida-Prieto M, Monserrat L, Laredo R, Rodriguez-Rey JC, Fernandez X, Castro-Beiras A: Mutational screening of phospholamban gene in hypertrophic and idiopathic dilated cardiomyopathy and functional study of the PLN -42 C>G mutation. Eur J Heart Fail. 2007, 9 (1): 37-43. 10.1016/j.ejheart.2006.04.007.
    Koss KL, Kranias EG: Phospholamban: a prominent regulator of myocardial contractility. Circ Res. 1996, 79 (6): 1059-1063.
    Schmitt JP, Kamisago M, Asahi M, Li GH, Ahmad F, Mende U, Kranias EG, MacLennan DH, Seidman JG, Seidman CE: Dilated cardiomyopathy and heart failure caused by a mutation in phospholamban. Science. 2003, 299 (5611): 1410-1413. 10.1126/science.1081578.
    Haghighi K, Kolokathis F, Pater L, Lynch RA, Asahi M, Gramolini AO, Fan GC, Tsiapras D, Hahn HS, Adamopoulos S, et al: Human phospholamban null results in lethal dilated cardiomyopathy revealing a critical difference between mouse and human. J Clin Invest. 2003, 111 (6): 869-876.
    Haghighi K, Kolokathis F, Gramolini AO, Waggoner JR, Pater L, Lynch RA, Fan GC, Tsiapras D, Parekh RR, Dorn GW, et al: A mutation in the human phospholamban gene, deleting arginine 14, results in lethal, hereditary cardiomyopathy. Proc Natl Acad Sci USA. 2006, 103 (5): 1388-1393. 10.1073/pnas.0510519103.
    Posch MG, Perrot A, Geier C, Boldt LH, Schmidt G, Lehmkuhl HB, Hetzer R, Dietz R, Gutberlet M, Haverkamp W, et al: Genetic deletion of arginine 14 in phospholamban causes dilated cardiomyopathy with attenuated electrocardiographic R amplitudes. Heart Rhythm. 2009, 6 (4): 480-486. 10.1016/j.hrthm.2009.01.016.
    Haghighi K, Chen G, Sato Y, Fan GC, He S, Kolokathis F, Pater L, Paraskevaidis I, Jones WK, Dorn GW, et al: A human phospholamban promoter polymorphism in dilated cardiomyopathy alters transcriptional regulation by glucocorticoids. Hum Mutat. 2008, 29 (5): 640-647. 10.1002/humu.20692.
    McKee PA, Castelli WP, McNamara PM, Kannel WB: The natural history of congestive heart failure: the Framingham study. N Engl J Med. 1971, 285 (26): 1441-1446.
    Richardson P, McKenna W, Bristow M, Maisch B, Mautner B, O'Connell J, Olsen E, Thiene G, Goodwin J, Gyarfas I, et al: Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of cardiomyopathies. Circulation. 1996, 93 (5): 841-842.
    Report of the WHO/ISFC task force on the definition and classification of cardiomyopathies. Br Heart J. 1980, 44 (6): 672-673. 10.1136/hrt.44.6.672.
    Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med. 1991, 325 (5): 293-302.
    Pereira AC, Sposito AC, Mota GF, Cunha RS, Herkenhoff FL, Mill JG, Krieger JE: Endothelial nitric oxide synthase gene variant modulates the relationship between serum cholesterol levels and blood pressure in the general population: new evidence for a direct effect of lipids in arterial blood pressure. Atherosclerosis. 2006, 184 (1): 193-200. 10.1016/j.atherosclerosis.2005.03.035.
    Sahn DJ, DeMaria A, Kisslo J, Weyman A: Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation. 1978, 58 (6): 1072-1083.
    Miller SA, Dykes DD, Polesky HF: A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988, 16 (3): 1215-10.1093/nar/16.3.1215.